FindTrial
Sign In

NEOADYUVANTE PHASE 2 STUDY USING GEMCITABIN ASSOCIATED WITH DOXORRUBICINE FOR THE TREATMENT OF BREAST CANCER CLINICAL STAGE III-B

NEOADYUVANTE PHASE 2 STUDY USING GEMCITABIN ASSOCIATED WITH DOXORRUBICINE FOR THE TREATMENT OF BREAST CANCER CLINICAL STAGE III-B

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REPEC
Registry ID
PER-003-00
Enrollment
32
Registered
2000-01-21
Start date
Unknown
Completion date
Unknown
Last updated
2023-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Group 1 Type of group
Gemcitabine: 1200 mg / m2 on days 1 and 8 every 21 days. Doxorubicin: 60 mg / m2 on day 1 every 21 days. Three cycles of the dose mentioned above.

Sponsors

ELI LILLY INTERAMERICA INC.,
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: NA

Exclusion criteria

Exclusion criteria: NA

Design outcomes

Primary

MeasureTime frame
Outcome name:NA Measure:NA Timepoints:NA—

Secondary

MeasureTime frame
Outcome name:NA Measure:NA Timepoints:NA—

Outcome results

None listed

Source: REPEC (via WHO ICTRP)